Patricia Pautier, MD, on Leiomyosarcoma: Doxorubicin and Trabectedin for First-Line Treatment
ASCO20 Virtual Scientific Program
Patricia Pautier, MD, of Institut Gustave Roussy, discusses final results of the phase II LMS-02 study, which showed the combination of doxorubicin and trabectedin to be an effective first-line therapy for patients with leiomyosarcoma, with an acceptable safety profile (Abstract 11506).
Howard A. Burris III, MD, FACP, FASCO, talks about some of the reports of research developments he is looking forward to and how future conferences could incorporate virtual presentations.
Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, talks with Thomas Powles, MD, PhD, of Queen Mary University of London, about the first study to demonstrate a survival advantage with avelumab for metastatic urothelial cancer. In the trial, avelumab improved median overall survival by 21.4 months compared with 14.3 months with best supportive care (Abstract LBA1).
Rachel E. Sanborn, MD, of the Providence Cancer Institute, discusses three key abstracts on EGFR-mutated non–small cell lung cancer: a final overall survival analysis of bevacizumab plus erlotinib; concurrent osimertinib plus gefitinib for first-line treatment; and first-line treatment with a tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy (Abstracts 9506, 9507, 9508).
As Thomas Powles, MD, PhD, of Queen Mary University of London, prepares to deliver his late-breaking presentation at the ASCO20 Virtual Scientific Program (LBA-1), he talks with Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, about current therapy: PD1/PDL1 inhibition in second-line treatment and as monotherapy in the first-line setting, as well as the concept of maintenance switch.
Sara A. Hurvitz, MD, of UCLA’s David Geffen School of Medicine, summarizes four breast cancer studies: KATHERINE, on adjuvant trastuzumab vs trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer; KAITLIN, on trastuzumab emtansine and pertuzumab vs trastuzumab, pertuzumab, and taxane after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer; TRAIN-2, on neoadjuvant chemotherapy with or without anthracyclines for HER2-positive disease; and PHERGain, on chemotherapy de-escalation using an FDG-PET/CT and pathologic response–adapted strategy in HER2-positive early breast cancer (Abstracts 500, 501, 502, and 503).